Postmenopausal hormone therapy and quality of life

Smith, A. J.; Hall, David; Grové, D.

doi:10.1016/j.ijgo.2006.07.003

Cited by 10 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another issue examined by the studies is the factors associated with QoL in postmenopausal women. However, these studies mostly focused on the effects of menopausal symptoms [1,[6][7][8], physical activity [9,10], hormone therapy [11][12][13], and physical problems such as vertebral fracture or osteoporosis [14][15][16]. Although several studies have investigated the impact of psychosomatic symptoms within menopausal symptom categories, these symptoms do not represent psychiatric morbidity adequately.…”

Section: Introductionmentioning

confidence: 99%

Quality of Life in Postmenopausal Women: The Impact of Depressive and Anxiety Disorders

Uğuz

Sahingoz

Gezginç

et al. 2011

Int J Psychiatry Med

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Quality of Life in Postmenopausal Women: The Impact of Depressive and Anxiety Disorders

Uğuz

Sahingoz

Gezginç

et al. 2011

Int J Psychiatry Med

View full text Add to dashboard Cite

show abstract

“…Questionnaires including quality of life after menopause (Utian, 2002) 1 , Quality of Life Index Questionnaire (Becker, 1999) 2 , 63-Item Health-related Quality of Life Questionnaire (Oxford University, 1992) 3 , Quality of Menopausal Life Questionnaire (McGill, 1992) 4 and Quality of Life and General Life Issues (World Health Organization, 1992) 5 are currently used to assess the quality of life. The UQOL questionnaire has been translated into Portuguese (12) and has been used in various studies on Spanish, Greek and South African women (13)(14)(15). Among these questionnaires, the UQOL questionnaire has been comparably more frequently used in other countries and more different studies on the quality of life after menopause.…”

Section: Introductionmentioning

confidence: 99%

Validity and Reliability of the Persian Version of the Utian Quality of Life Scale (UQOL)

Balanian¹,

Fallahzadeh²,

Sharifabad³

2020

jbe

View full text Add to dashboard Cite

Background:Menopause can have adverse effects on the quality of life of postmenopausal women. The main purpose of this study was to determine the Validity and Reliability of the Persian version of the Utian Quality of Life Scale (UQOL) in iranian postmenopausal women in 2019 Methods: The questionnaire was first translated into Persian. After its adaptation with the original version and backward translating it into English, the face and content validity were assessed by a group of experienced experts. To this end, exploratory factor analysis was performed by Principal Factor Analysis method with varimax rotation. Convergent validity was assessed by correlating the Persian version of UQOL and the 36-Item Short Form Health Survey (SF-36). Finally, the mean quality of life score of postmenopausal women in different domains as well as its mean in different domains based on age, education level, menopausal age, and number of children were calculated. Results: Regarding reliability, the alpha coefficient was obtained 0.66 for occupation domain, 0.52 for health domain, 0.50 for emotional domain, and 0.90 for sex domain. There was a significant relationship between quality of life and age, menopausal age, occupation and number of children in all domains in menopausal women. There was a significant relationship between BMI and quality of life score in postmenopausal women only in physical health domain. Conclusion:it seems this questionnaire can’t be used in research on the quality of life of postmenopausal women.

show abstract

Do estrogen or selective estrogen receptor modulators improve quality of life for women with postmenopausal osteoporosis?

Gold

Silverman²

2007

Curr Osteoporos Rep

View full text Add to dashboard Cite

Osteoporotic fractures result in significant deficits in health-related quality of life (HRQOL). The accumulation of deficits resulting from osteoporosis and fractures is now recognized as a major cause of reduced HRQOL in women after the menopause and in later life. Some of these same postmenopausal women may also have deficits in HRQOL related to vasomotor symptoms during the menopausal transition. Although estrogen therapy has not been shown to improve overall HRQOL in late postmenopausal women in randomized, controlled trials, it may improve menopausal symptoms. In contrast, selective estrogen receptor modulators (SERMs) such as raloxifene may increase vasomotor symptoms. Although estrogen is not indicated for the primary prevention of osteoporosis, estrogen therapy may be considered for the postmenopausal woman at risk of osteoporotic fracture who is symptomatic and who is not at high risk of breast cancer or cardiovascular events. Raloxifene decreases risk of invasive breast cancer and may be considered in women at high risk of breast cancer. Decision making about osteoporosis treatment should also consider the impact of the treatment on HRQOL.

show abstract

Postmenopausal hormone therapy and quality of life

Abstract: This study found that post-menopausal South African women experienced that HT had a positive effect on global quality of life.

Cited by 10 publications

References 20 publications

Quality of Life in Postmenopausal Women: The Impact of Depressive and Anxiety Disorders

Quality of Life in Postmenopausal Women: The Impact of Depressive and Anxiety Disorders

Validity and Reliability of the Persian Version of the Utian Quality of Life Scale (UQOL)

Do estrogen or selective estrogen receptor modulators improve quality of life for women with postmenopausal osteoporosis?

Contact Info

Product

Resources

About